Immune Reconstitution and Early Infectious Complications Following Nonmyeloablative Hematopoietic Stem Cell Transplantation
暂无分享,去创建一个
F. Locatelli | G. Rossi | D. Cirillo | A. Busca | P. Omedé | P. Scaravaglio | V. Ghisetti | A. Barbui | A. Dall'omo | A. Serra | M. Falda | S. Aliberti | E. Lovisone | P. Omedè
[1] E. Spierings,et al. Histocompatibility. , 2018, Transplantation proceedings.
[2] J. Garcia-conde,et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. , 2002, Blood.
[3] M. Maris,et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] C. Craddock,et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. , 2002, Blood.
[5] D. Rizzieri,et al. Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] J. Mary,et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients , 2001, British journal of haematology.
[7] J. Wagner,et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] B. Bolwell,et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.
[9] D. Douek,et al. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism , 2001, Bone Marrow Transplantation.
[10] C. Solano,et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.
[11] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[12] R. Childs,et al. CMV reactivation in nonmyeloablative HSCT , 2001, Bone Marrow Transplantation.
[13] C. Siegrist,et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. , 2000, Blood.
[14] R. Bouabdallah,et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation , 2000, Bone Marrow Transplantation.
[15] R. Naumann,et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin , 2000, Bone Marrow Transplantation.
[16] C. Payá,et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients , 2000, Clinical transplantation.
[17] R. Vij,et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[20] Gregory T Stelzer,et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. , 1997, Cytometry.
[21] R. Hoover,et al. Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.
[22] H. Grosse-wilde,et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. , 1996, Blood.
[23] C. Mackall,et al. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. , 1993, Blood.
[24] G. Heller,et al. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. , 1990, Blood.
[25] D. Blaise,et al. IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.
[26] Jaap M Middeldorp,et al. Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. , 1985, Blood.
[27] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[28] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[30] D. Porter,et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] S. Mineishi,et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin , 2002, Bone Marrow Transplantation.